Celecoxib was compared to ibuprofen and naproxen in a randomized controlled trial of over 80,000 patients with osteoarthritis or rheumatoid arthritis. The trial found celecoxib to be noninferior to ibuprofen and naproxen for cardiovascular safety, with celecoxib demonstrating a lower risk of major cardiovascular events. Subgroup analyses found the reduced cardiovascular risk with celecoxib was consistent across high-risk patients.